Sugi Predict

Sugi Predict / Compounds / SCHEMBL724112

SCHEMBL724112

SCHEMBL724112

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.65
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ KDM4E B2RXH2 2/20 0.64
▸ TDP1 Q9NUW8 1/20 0.61
▸ PDE4A P27815 1/20 0.44
▸ USP2 O75604 1/20 0.41
▸ SLCO1B1 Q9Y6L6 1/20 0.41
▸ PNP P00491 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9444652 1.00 LMNA (0.65) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL29344590 1.00 LMNA (0.65) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL5551085 1.00 LMNA (0.65) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL8533676 0.94 KDM4E (0.56) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL9444635 0.92 KDM4E (0.56) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL1399177 0.90 KDM4E (0.54) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL6983494 0.90 KDM4E (0.54) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL7694338 0.90 KDM4E (0.54) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL7702972 0.89 KDM4E (0.58) LMNAL3MBTL1KDM4ETDP1PDE4A
SCHEMBL22642691 0.89 KDM4E (0.58) LMNAL3MBTL1KDM4ETDP1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6258840-B1 ANTITUMOR AGENTS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS OF KINASES COBRA THERAPEUTICS LIMITED (GB) 2001-07-10 — — US claimed
EP-0912541-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) Cobra Therapeutics Limited (GB) 1999-05-06 — — EP claimed
WO-1997049693-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) COBRA THERAPEUTICS LIMITED (GB) 1997-12-31 — — WO claimed
WO-2024151890-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. (US) 2024-07-18 — — WO disclosed
WO-2023146892-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
US-8540966-B2 Contrast agents endowed with high relaxivity BRACCO IMAGING S.P.A. (IT) 2013-09-24 — — US disclosed
US-20130053506-A1 FLUORINE COMPOUND AND ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION USING SAME DIC CORPORATION (JP) 2013-02-28 — — US disclosed
CN-101090739-B 1, 4-bis (carboxymethyl) amino-6-methyl-perhydro-1, 4-diaza (AAZTA) derivatives as ligands for high relaxation contrast agents in magnetic resonance imaging BRACCO IMAGING SPA 2012-10-10 — — CN disclosed
US-20120048295-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2012-03-01 — — US disclosed
US-20110256067-A1 Contrast agents endowed with high relaxivity BRACCO IMAGING SPA (IT) 2011-10-20 — — US disclosed
CN-1993357-B High relaxation contrast agents containing chelating moieties with polyhydroxylated substituents for magnetic resonance imaging (MRI) BRACCO IMAGING SPA 2011-10-19 — — CN disclosed
EP-0835140-A2 METAL COMPLEXES OF POLYAMINOACIDS, AND THEIR UTILIZATION IN DIAGNOSTIC IMAGING GUERBET S.A. (FR) 1998-04-15 — — EP disclosed
WO-1997049693-A1 ANALOGUES OR DERIVATIVES OF QUERCETIN (PRODRUGS) COBRA THERAPEUTICS LIMITED (GB) 1997-12-31 — — WO disclosed
US-5693311-A Polyiodinated compounds, process for preparing them and diagnostic compositions GUERBET S.A. (FR) 1997-12-02 — — US disclosed
US-5631389-A SUCCINAMIDES WITH SUGAR GROUPS, POLLUTION CONTROL, BIODEGRADABLE LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1997-05-20 — — US disclosed
WO-1997001359-A2 METAL COMPLEXES OF POLYAMINOACIDS, AND THEIR UTILIZATION IN DIAGNOSTIC IMAGING GUERBET S.A. (FR) 1997-01-16 — — WO disclosed
US-5541341-A CARBOHYDRATE BASED SURFACTANTS LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1996-07-30 — — US disclosed
EP-0675105-A1 Polyiodinated compounds, process for their preparation and diagnostic composition GUERBET S.A. (FR) 1995-10-04 — — EP disclosed
EP-0536939-A1 Process for the production of aminopolyols CERESTAR HOLDING BV (NL) 1993-04-14 — — EP disclosed
US-5112530-A Heavy metal and alkaline earth metal complexing agents BASF AKTIENGESELLSCHAFT (DE) 1992-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110256067-A1 Contrast agents endowed with high relaxivity SLC40A1, SLC67A1, SLC19A1 LMNA 2401/4885L3MBTL1 3245/4885KDM4E 4124/4885
US-20130053506-A1 FLUORINE COMPOUND AND ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION USING SAME RER1, AFF1, AFF4 LMNA 2724/4885L3MBTL1 1498/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.